20mg/ml
Trade Name
Tyruko
Concentrate for solution for infusion
Request Type
Registration
Drug Type
Biological Drug
Approval Date
SFDA Approved Use
Multiple Sclerosis (MS)
It is indicated as single disease modifying therapy in adults with highly active relapsing
remitting multiple sclerosis (RRMS) for the following patient groups:
• Patients with highly active disease despite a full and adequate course of treatment with at least
disease modifying therapy (DMT).
Or
• Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in
year, and with 1 or more Gadolinium enhancing lesions on brain Magnetic Resonance Imaging
(MRI) or a significant increase in T2 lesion load as compared to a previous recent MRI.
It is indicated as single disease modifying therapy in adults with highly active relapsing
remitting multiple sclerosis (RRMS) for the following patient groups:
• Patients with highly active disease despite a full and adequate course of treatment with at least
disease modifying therapy (DMT).
Or
• Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in
year, and with 1 or more Gadolinium enhancing lesions on brain Magnetic Resonance Imaging
(MRI) or a significant increase in T2 lesion load as compared to a previous recent MRI.